Cell differentiation is determined by a certain set of transcription factors such as MyoD in myogenesis. However, transcription factors that play a positive role in phenotypic gene expression in skeletal cells are largely unknown, except the recently identified CBFA1. Scleraxis is a helix-loop-helix-type transcription factor whose transcripts are expressed in sclerotome and in a certain set of skeletal cells; however, nothing is known about its function with regard to the regulation of cell function. To examine possible roles of scleraxis, we overexpressed scleraxis in osteoblastic ROS17/2.8 cells, which express low levels of scleraxis. Scleraxis overexpression enhanced expression of the aggrecan gene, which is not normally expressed at high levels in these osteoblastic cells. Overexpression of scleraxis also increased mRNA levels of type II collagen and osteopontin while suppressing expression of osteoblast phenotype-related genes encoding type I collagen and alkaline phosphatase. Transient transfection experiments indicated that scleraxis enhanced the chloramphenicol acetyltransferase activity of the reporter construct AgCAT-8, which contained an 8-kilobase pair (kb) fragment of the aggrecan gene including both the promoter and its first intron. Deletion analysis identified a 1-kb region that is responsive to scleraxis within the aggrecan gene. This region contains two adjacent E-box sequences. A 29-base pair DNA fragment (AgE) containing these E-box sequences bound to proteins in the ROS17/2.8 cell nuclear extracts as well as to in vitro translated scleraxis. This binding was competed with unlabeled AgE, but not with a mutated E-box DNA sequence (mAgE), indicating the specificity of the binding activity. The AgE binding activity in the ROS17/2.8 cell nuclear extracts was enhanced in the cells overexpressing scleraxis and was supershifted by the antiserum raised against scleraxis. Furthermore, AgE, but not mAgE, conferred responsiveness to scleraxis overexpression to a heterologous promoter. Finally, replacement mutation of the AgE sequence within the 2.5-kb AgCAT-1 construct significantly reduced its responsiveness to scleraxis. These results indicate that overexpression of a single helixloop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression via binding to the E-box-containing AgE sequence in ROS17/2.8 cells.
Determination of specific cell fate is under the control of a certain set of various types of transcription factors. Among these, the basic helix-loop-helix (bHLH) 1 -type transcription factor family is well known for its critical role in the transcriptional regulation of cellular differentiation in myogenesis, hematopoiesis, and neurogenesis (1) (2) (3) (4) . In this machinery, tissuespecific gene transcription is positively regulated by formation of heterodimers between tissue-specific bHLH proteins and ubiquitous bHLH proteins such as E12/E47 (5), whereas it is negatively regulated by another type of regulatory HLH protein lacking the basic DNA-binding domain, such as Id (6) . These heterodimers interact with cis-acting elements (CANNTG) called E-boxes, which are located in the promoter/ enhancer regions of tissue-specific genes (1) (2) (3) (4) 7) .
Although no skeletal tissue-specific HLH transcription factors have yet been identified, E-box sites are present in the promoters of the genes encoding osteocalcin (7), osteopontin, 2 and alkaline phosphatase, 2 which are the markers of osteoblastic differentiation (9, 10) . Previously, we reported that osteoblasts express ubiquitous type HLH transcription factors and that expression of such HLH transcription factors is under the control of calciotropic hormones and cytokines (7, 11) .
Scleraxis has recently been identified as a basic helix-loophelix transcription factor (12) . Its mRNA is expressed in mouse embryos between days 9.5 and 10.5 post-coitum in sclerotomes and in mesenchymal cells of the body wall and limb buds. Subsequently, scleraxis is expressed at high levels within mesenchymal precursors of the axial and appendicular skeletons and in cranial mesenchyme in advance of chondrogenesis (12) . Scleraxis is also expressed in osteoblastic osteosarcoma ROS17/ 2.8 cells, although at low levels, and its expression is regulated by transforming growth factor-␤, which has been implicated in bone formation (13) . However, nothing was known about its functional role in the regulation of cell fate.
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We found that scleraxis enhanced expression of the aggrecan gene and suppressed expression of the type I collagen and alkaline phosphatase genes in these osteoblastic ROS17/2.8 cells. Analysis of the aggrecan promoter showed that scleraxis enhanced aggrecan gene transcription via its E-box-containing sequence (AgE). These data suggest that scleraxis could be one of the key regulatory transcription factors that are involved in the positive regulation of genes encoding proteins of chondrogenic phenotype.
MATERIALS AND METHODS
Cell Culture-ROS17/2.8 cells were provided by Dr. Gideon Rodan (Merck Research Laboratories) and were maintained in modified F-12 medium supplemented with 5% fetal bovine serum (FBS) (14) . All cultures were fed with fresh medium every 2-3 days.
Stable DNA Transfection-Stable transfections were carried out by employing the calcium phosphate precipitation technique as described by Parker and Stark (15) . Approximately 5 ϫ 10 5 cells were cotransfected with 10 g of expression vector plasmid containing scleraxis cDNA and 0.5 g of neo expression vector. Other sets of cells were transfected with the neo vector alone. After a 4-h incubation, the cells were treated with 15% glycerol for 30 s. Approximately 24 h later, the cells were trypsinized, replated at 6 ϫ 10 4 cells in a 56-cm 2 dish, and fed with modified F-12 medium containing 200 g/ml G418 (Life Technologies, Inc.) as described (16) . The medium was supplemented with 5% FBS. After 1 month of culture, individual clones were isolated. RNA was extracted and subjected to Northern blot analysis.
RNA Preparation and Northern Analysis-Total RNA was extracted according to the acid guanidium thiocyanate/phenol/chloroform method (17) . Total cellular RNA was subjected to Northern analysis by fractionation on 1.0% agarose gels containing 0.66 M formaldehyde. The RNAs were transferred to nylon filters (Hybond-N, Amersham Corp.) by electroblotting for 18 h (18). A 1.2-kb scleraxis cDNA probe was labeled with [␣-32 P]dCTP (New Life Science Products) using random primers and the Klenow fragment (Pharmacia, Uppsala, Sweden) (19) . Complementary DNAs for osteopontin and alkaline phosphatase were gifts from Dr. Gideon Rodan; ␣1(I) collagen cDNA was provided by Dr. Barbara Kream (University of Connecticut); and glyceraldehyde-6-phosphate dehydrogenase (GAPDH) was provided by Dr. Sevgi Rodan. Filters were hybridized to the probes overnight at 42°C in hybridization solution containing 50% formaldehyde, 5 ϫ SSC (1 ϫ SSC ϭ 0.15 M NaCl and 10 mM sodium citrate), 5 ϫ Denhardt's solution, 0.1% SDS, and 50 mg/ml sheared and denatured herring sperm DNA. Membranes were washed at 65°C in 0.2 ϫ SSC and 0.1% SDS and exposed to x-ray films at Ϫ70°C using intensifying screens.
Transient DNA Transfections and CAT Assays-Transfection of plasmid DNA into ROS17/2.8 cells was performed using DNA-lipid complexes (20) . The cells were cotransfected with 1 g of scleraxis expression vector (12) and 1 g of aggrecan reporter plasmids (AgCAT-8, AgCAT-1, or AgCAT-6 containing a 8-, 2.5-, or 1-kb fragment of the promoter/exon 1 (encoding the 5Ј-untranslated region)/intron 1 segments of the mouse aggrecan gene, respectively) (21) . The scleraxis expression vector was also cotransfected with AgE-CAT or mAgE-CAT, which were constructed by inserting a 29-base pair double-stranded synthetic oligonucleotide corresponding to a region (designated as AgE) from positions ϩ219 to ϩ247 into the BglII site of the pCAT™ promoter plasmid (Promega). The oligonucleotides contained either two E-boxes (AgE-CAT, 5Ј-gatctCGGCTAGCATCTGACGCAGGTGCCGAGGGa-3Ј; E-box, underlined) or two mutated E-boxes (mAgE-CAT, 5Ј-gatctCGGCTAGAAAAAAACGTTTTTTCCGAGGGa-3Ј). Bluescript SK ϩ was used as a control (22) . Another mutant construct (mAgCAT-1) was prepared by introducing a replacement mutation (mAg, 5Ј-AAAA-AAACGTTTTTT-3Ј) in the context of the 2.5-kb aggrecan promoter (AgCAT-1) according to the method described (23) . The cells were exposed to the DNA solution for 3 h and then cultured in fresh F-12 medium supplemented with 5% FBS. After 48 h, the cell extracts were prepared for analysis of CAT activity. Equivalent amounts of cellular proteins were incubated in the reaction buffer (0.25 M Tris-HCl, pH 8.0, 40 mM acetyl-CoA (Sigma), and 1.85 GBq/mmol [ 14 C]chloramphenicol (Amersham Corp.)) overnight at 37°C. The level of acetylation was examined by TLC followed by autoradiography of the TLC plates. Quantitation of acetylation ratios was performed with a Bioimaging Analyzer Bas 2000 (Fuji Film Inc., Tokyo, Japan).
In Vitro Transcription and Translation-RNA was synthesized in a 25-l reaction mixture for 1 h at 37°C with a substrate of 1 g of linearized DNA and Cap analog (Life Technologies, Inc.) and T7 polym- For EMSAs, a 29-base pair double-stranded synthetic oligonucleotide corresponding to the sequence (AgE) from positions ϩ219 to ϩ247 containing the E-boxes was used. A BglII site was attached to each end of the oligonucleotides (indicated by lower-case letters below). The AgE sequence of the upper strand of this oligonucleotide was as follows: top strand, 5Ј-gatctCGGCTAGCATCTGACGCAGGTGCCGAGGGa-3Ј; and bottom strand, 5Ј-gatctCCCTCGGCACCTGCGTCAGATGCTAGCCGa-3Ј with E-box underlined). These oligonucleotides were annealed to form the AgE sequence probe and labeled by a filling-in reaction at their 5Ј-protruded ends using [␣-32 P]dCTP and the Klenow fragment. Unincorporated label was removed by passing the probes over Sephadex G-50 columns. Aliquots of 20,000 cpm of the probe were incubated with 15 g of nuclear protein for 15 min at 30°C in a 20-l reaction mixture containing 20 mM Hepes, pH 7.5, 100 mM KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol, 20% glycerol, 5 g of bovine serum albumin (Sigma), and 2 g of poly(dI-dC) (Pharmacia Biotech Inc.). For competition experiments, a 100-fold molar excess of double-stranded unlabeled probes was included in the binding reactions. The competitors were either the unlabeled AgE sequence as described above or the mutated AgE sequence designated as mAgE. We also used scleraxis E-box oligonucleotides (ScxE) and mutated ScxE oligonucleotides (mScxE) as competitors since the ScxE oligonucleotide containing an E-box sequence (5Ј-CCGAACACATGTGCCCGC-3Ј; with the E-box underlined) was formerly reported (12) to be preferentially bound by scleraxis. Within the ScxE sequence, only the E-box was mutated to produce mScxE (from CATGTG to AATTTA). These double-stranded oligonucleotides used as competitors were incubated with the nuclear extracts for 15 min before the addition of the probe. The DNA-protein complexes were fractionated on a 4% polyacrylamide gel as described (7). For the supershift experiments, 1-l aliquots of 0.1 g/l IgG or antiserum raised against scleraxis were added to the reaction mixture and incubated for 20 min before electrophoresis.
FIG. 1.
Effects of scleraxis overexpression on expression of genes encoding phenotypic markers for osteoblasts and chondrocytes in stably transfected ROS17/2.8 cells. ROS17/2.8 cells were stably transfected with a scleraxis expression vector and a neo resistance vector using the calcium precipitation technique. The cells were maintained in modified F-12 medium supplemented with 5% FBS containing 200 mg/ml G418. Two G418-resistant ROS17/2.8 transformant clones (S1 and S2) were established, and their RNAs were prepared. Northern blot analysis was conducted as described under "Materials and Methods." The levels of the messenger RNAs for scleraxis (Scx), aggrecan (Agg), type II collagen (II Col), type I collagen (I Col), alkaline phosphatase (AP), osteopontin (OP), and osteocalcin (OC) were examined. The positions of scleraxis, aggrecan, type I and II collagens, alkaline phosphatase, osteopontin, and GAPDH are indicated.
RESULTS

Overexpression of Scleraxis Induces Expression of Cartilage
Phenotypic Markers in ROS17/2.8 Cells-To examine functional roles of scleraxis in the regulation of skeletal cell phenotype expression, we transfected a scleraxis expression vector into several types of cell lines. Since C3H10T1/2 cells are known to be pluripotent and can give rise to several types of mesenchymal cells, we first tried scleraxis transfection into these cells. However, we did not find any alteration in their expression of genes related to skeletal phenotypes. Since we previously found that scleraxis is expressed in the osteoblastic cell line ROS17/2.8, although at low levels, we then tried to overexpress scleraxis in these cells. We generated permanent transfectant cell lines by introducing a scleraxis expression vector and a neo expression vector into ROS17/2.8 cells. Two G418-resistant transformant clones (S1 and S2) were isolated. Northern analysis of the RNA prepared from these cells is shown in Fig. 1 . Scleraxis overexpression in the transfected cells was confirmed by the increased levels of the exogenous scleraxis mRNA in the S1 and S2 clones (Fig. 1, Scx panel) . To our surprise, scleraxis overexpression in the osteoblast-like cells enhanced expression of mRNAs encoding cartilage-specific markers in the S1 and S2 clones (Fig. 1 ) compared with control neo-transfected ROS17/2.8 cells (Fig. 1, lane N) . Aggrecan mRNA expression was most potently enhanced in the permanent scleraxis transfectants (Fig. 1, Agg panel) . Interestingly, type II collagen mRNA was expressed at a low level in control neo-transfected ROS17/2.8 cells (Fig. 1) , and scleraxis overexpression also enhanced type II collagen mRNA expression (Fig. 1, II Col panel) . Furthermore, the enhanced expression of cartilage phenotype-related genes was accompanied by the suppression of the mRNA levels of type I collagen and alkaline phosphatase (Fig. 1, I Col and AP panels) . These data reveal that scleraxis functions in modulating expression of several skeletal phenotype-related genes. Scleraxis overexpression also enhanced mRNA expression of osteopontin, which has been known to be expressed both in osteoblasts and chondrocytes (Fig. 1, OP panel) . Overexpression of scleraxis did not alter GAPDH message levels in these clones compared with control neo-transfected ROS17/2.8 cells, indicating the specificity of the scleraxis effect (Fig. 1, GAPDH panel) . The levels of expression of the examined genes in the control neo-transfected -12) , or AgCAT-8 ( lanes 13-16) ; and 1 mg of scleraxis (Scx) expression vector (lanes 3, 4, 7, 8, 11, 12, 15, and 16) 2, 5, 6, 9, 10, 13, and 14) . The AgCAT-1, AgCAT-6, and AgCAT-8 constructs contain 2.5-, 1-, and 8-kb aggrecan gene fragments, respectively, including the first exon. The cells were also transfected with pSV2CAT as a positive control (lanes 1-4) . The transfected cells were incubated in F-12 medium supplemented with 5% FBS for 48 h. CAT activity was determined as described under "Materials and Methods. "   FIG. 3 . The E-box-containing region in the aggrecan gene (AgE) binds to proteins in the nuclear extract prepared from ROS17/2.8 cells. EMSAs were performed as described under "Materials and Methods." The AgE sequence corresponding to the region of the aggrecan gene from positions ϩ219 to ϩ247 containing two E-boxes (CATCTG and CAGGTG) was synthesized as a double-stranded oligonucleotide and used as a probe. The nuclear extract prepared from ROS17/2.8 cells was incubated with radiolabeled AgE probe (lane 1), and the reaction was competed with a 100-fold molar excess of unlabeled AgE (lanes 2 
ROS17/2.8 cells were comparable to those of the parental nontransfected ROS17/2.8 cells (data not shown).
Scleraxis Enhances the Transcriptional Activity of the Aggrecan Gene-To examine whether scleraxis activates the transcriptional activity of the aggrecan gene, a CAT reporter gene construct (AgCAT-8) containing an 8-kb fragment of the mouse aggrecan gene including the promoter, the first exon, and a part of the first intron ( Fig. 2A ) (21) was cotransfected with the scleraxis expression vector into ROS17/2.8 cells. Scleraxis overexpression enhanced the transcriptional activity of the Ag-CAT-8 construct severalfold (Fig. 2B, lanes 13 and 14 versus  lanes 15 and 16) . To further determine whether any particular region of the aggrecan gene responds to scleraxis overexpression, we also examined the CAT activities of the two other deletion constructs, AgCAT-1 (2.5 kb) and AgCAT-6 (1 kb). The CAT activities of these constructs were also enhanced by cotransfection with the scleraxis expression vector (Fig. 2B , lanes 5 and 6 versus lanes 7 and 8 and lanes 9 and 10 versus lanes 11 and 12, respectively). On the other hand, scleraxis overexpression did not affect the activity of the control pSV2CAT construct, indicating the specificity of the effect of scleraxis on the aggrecan promoter (Fig. 2B, lanes 1 and 2 versus lanes 3 and 4) .
Proteins in the Nuclear Extract Prepared from ROS17/2.8 Cells Bind to the E-box-containing AgE Sequence Present in the
Aggrecan Gene-Within the 1-kb aggrecan gene fragment, we identified a 29-base pair region, which we designated as AgE (5Ј-CGGCTAGCATCTGACGCAGGTGCCGAGGG-3Ј), containing two adjacently positioned E-box sequences (underlined) at positions ϩ226 to ϩ240. To examine whether AgE is the target site of scleraxis, we conducted EMSAs using AgE as a probe. As shown in Fig. 3 (lane 1) , AgE bound the proteins in nuclear extracts prepared from ROS17/2.8 cells in the EMSA. This binding was competed with the presence of a 100-fold molar excess of unlabeled AgE (Fig. 3, lane 2 ), but not with mAgE (lane 3), which contains substitution mutations (underlined) in the E-box sequences (5Ј-CGGCTAGAAAAAAACGTTTTTTC-CGAGGG-3Ј), indicating the specificity of the binding activity. The binding activity was also competed with a 100-fold molar excess of the ScxE sequence (Fig. 3, lane 4) , which is another E-box sequence (CATGTG) known to bind scleraxis preferentially (12), but it was not competed with the mScxE sequence, which contains substitution mutations in the E-box (from CAT-GTG to AATTTA) (lane 5). This is consistent with our previous observation that scleraxis is expressed in these cells, although at a low level (Fig. 1, Scx panel, lane N) (13) . This band was supershifted when the antiserum raised against scleraxis was added to the reaction mixture, which was then incubated for 20 min before EMSA (Fig. 3, lane 6) . IgG alone did not supershift the band (Fig. 3, lane 7) , and the supershifted band was competed with the presence of an excess amount of unlabeled AgE (lane 8).
To further examine whether the AgE sequence directly binds scleraxis, scleraxis protein was synthesized in vitro and subjected to EMSA. As shown in Fig. 4A , AgE bound scleraxis protein (lane 1), and this band was competed with AgE or ScxE (lanes 2 and 4, respectively), but not with mAgE or mScxE (lanes 3 and 5, respectively). Antiserum against Scx, but not IgG, supershifted the band (Fig. 4A, lanes 6 and 7, respectively), and the supershifted band was also competed with AgE (lane 8). For confirmation, the in vitro translation product was visualized by labeling the protein and analysis on SDS-polyacrylamide gel, which showed two bands, and the apparent molecular size of the top band was ϳ20 kDa (Fig. 4B) , which is slightly smaller than the estimated size of scleraxis (22 kDa), possibly due to truncation during in vitro translation. AgE binding to nuclear proteins was increased in the nuclear extract prepared from scleraxis-overexpressing ROS17/2.8 cells (Fig. 5, lane 3 , thick arrow) compared with the control cells (lane 2). Furthermore, an additional slower mobility band was observed in scleraxis-overexpressing cells (Fig. 5, lane 3, thin  arrow) . The addition of the antiserum against scleraxis supershifted these bands to yield the one major slowest mobility band (Fig. 5, lanes 4 and 5, arrowhead) .
The Aggrecan Gene E-box-containing Sequence (AgE) Confers Responsiveness to Scleraxis Overexpression to a Heterologous FIG. 5 . AgE binding activity is enhanced in the nuclear extract prepared from S1 clonal cells. EMSAs were performed as described under "Materials and Methods." The AgE sequence corresponding to the region of the aggrecan gene from positions ϩ219 to ϩ247 containing two E-boxes (CATCTG and CAGGTG) was synthesized as a doublestranded oligonucleotide and used as a probe. Lane 1, free AgE probe alone; lanes 2 and 4, nuclear extract prepared from ROS17/2.8 cells (C); lanes 3 and 5, nuclear extract prepared from S1 clonal cells (S). In lanes 4 and 5, antiserum against scleraxis (Scx) was added to the reaction. The arrows indicate specific DNA-protein complexes, and the arrowhead indicates the supershifted band.
FIG. 6. AgE sequence confers responsiveness to scleraxis overexpression to a heterologous promoter. A, the AgE-CAT construct contains one copy of the AgE sequence in the 5Ј to 3Ј direction corresponding to positions ϩ219 to ϩ247 of the aggrecan gene containing two E-box sequences (CATCTG and CAGGTG), whereas the mAgE-CAT construct contains one copy of the mAgE sequence that has substitution mutations in the E-box sequence (CATCTG to AAAAAA and CAGGTG to TTTTTT). B, ROS17/2.8 cells were cotransfected with 1 g of reporter plasmid, AgE-CAT (lanes 1-4) or mAgE-CAT (lanes 5-8) , and 1 g of scleraxis (Scx) expression vector ( lanes 3, 4, 7, 8, 11, and 12 ) or 1 g of Bluescript SK
ϩ (lanes 1, 2, 5, 6 , 9, and 10). The cells were also transfected with pSV2CAT as a positive control (lanes 9 -12) . The transfected cells were cultured in F-12 medium supplemented with 5% FBS for 24 h. CAT activity was determined as described under "Materials and Methods."
Promoter-We then examined whether the AgE sequence is the site that is responsible for the scleraxis activation of transcription. To do this, AgE and mAgE were inserted in front of the heterologous SV40 promoter to yield two constructs, AgE-CAT and mAgE-CAT, respectively (Fig. 6A) . Each construct was cotransfected into ROS17/2.8 cells with the scleraxis expression vector or Bluescript SK ϩ as a control. As shown in Fig. 6B,  (lanes 1 and 2 versus lanes 3 and 4) , scleraxis cotransfection enhanced the transcriptional activity of AgE-CAT severalfold. This scleraxis activation was no longer observed when mAgE-CAT and the scleraxis expression vector were cotransfected (Fig. 6B, lanes 5 and 6 versus lanes 7 and 8) . The transcriptional activity of pSV2CAT in these cells was not affected by cotransfection with the scleraxis expression vector (Fig. 6B,  lanes 9 and 10 versus 11 and 12) , indicating the specificity of the scleraxis effects on the E-box-containing sequence (AgE) in the aggrecan gene.
To further confirm that the AgE sequence is critical to mediate scleraxis-dependent regulation in the context of the aggrecan gene, we introduced mutations into AgE in Ag-1, which contains a 2.5-kb fragment of the aggrecan gene. This 2.5-kb aggrecan gene fragment with a mutation in AgE was ligated in front of CAT to yield mAgCAT-1 (Fig. 7A) . As shown in Fig. 7B  (lanes 5 and 6 versus lanes 7 and 8) , scleraxis overexpression enhanced AgCAT-1 expression, whereas the effect of scleraxis overexpression was significantly reduced by introducing a mutation in AgE in the context of the 2.5-kb fragment. These data indicate that the AgE sequence is the scleraxis target site in the aggrecan gene.
DISCUSSION
This study indicates for the first time that overexpression of a single type transcription factor induces expression of the aggrecan gene in osteoblastic osteosarcoma ROS17/2.8 cells.
Members of the helix-loop-helix-type transcription factor family have been previously implicated in differentiation of muscle cells or nerve cells (1-4) . However, nothing has been implicated in the positive regulation of the transactivation of skeletal tissue-specific gene expression except the recently identified CBFA1, which plays a crucial role in osteoblast differentiation (25) (26) (27) . This report identifies scleraxis, a recently cloned member of the helix-loop-helix-type transcription factor family, as a regulator of chondrocyte-specific gene expression. In support for our observation, we also found that scleraxis is expressed at a high level in chondrocytes, such as TC6, which express the aggrecan and type II collagen genes. 2 Overexpression of scleraxis enhanced expression of at least two cartilage-specific genes encoding aggrecan and type II collagen. Furthermore, our analysis of the aggrecan gene showed that the scleraxis effect was mediated by an 8-kb fragment. Further analysis of the 8-kb fragment identified that a 29-base pair region (AgE) located from positions ϩ219 to ϩ247, which contains two adjacent E-box sequences (positions ϩ226 to ϩ240), is responsible for the scleraxis binding and enhancement of aggrecan promoter activity. These results clearly indicate that the aggrecan gene is a direct target of scleraxis and that scleraxis exerts its effect via binding to E-box sequences in the aggrecan gene.
Differentiation of mesenchymal cells into chondrocytes is characterized by expression of markers specific to cartilage (28) . In the initial attempts to examine scleraxis function, we overexpressed scleraxis in C3H10T1/2 cells, but these experiments failed to show any alteration in expression of skeletal tissue-specific genes in these fibroblasts. Therefore, we examined ROS17/2.8 cells, which, as we reported (13), expressed relatively low levels of scleraxis. In ROS17/2.8 cells, the effect of scleraxis overexpression is most potent in the activation of aggrecan gene expression. In addition, the type II collagen mRNA level is also increased. We have isolated three additional G418-resistant clones, and in all of the three additional clones, aggrecan mRNA levels were enhanced, but GAPDH mRNA levels were not altered (data not shown). Based on these observations, we assume that scleraxis may act as a regulatory transcription factor for expression of cartilage-specific genes, although further analyses of other cartilage-specific genes should follow. There is a certain difference in the levels of induction by scleraxis on the aggrecan gene and those on the type II collagen gene. The reasons for this are not clear at this point.
The effect of scleraxis on expression of the aggrecan and type II collagen genes appears to be specific to this bHLH transcription factor since we did not see such change in stable overexpression of another related but distinct bHLH transcription factor, paraxis (29) , which served as as control, in either C3H10T1/2 or ROS17/2.8 cells. (Paraxis mRNA was undetectable in these cells.) It is also intriguing to identify the reason(s) why scleraxis could enhance the aggrecan gene in ROS17/2.8 cells, but not in C3H10T1/2 cells. Since scleraxis did not induce chondrocyte-specific gene expression in C3H10T1/2 cells, it is likely that scleraxis acts as a downstream transcription factor, with a particularly strong effect on aggrecan gene expression.
Another feature of scleraxis-overexpressing osteoblastic cells FIG. 7 . The AgE sequence in the context of the aggrecan gene confers responsiveness to scleraxis overexpression. A, the Ag-CAT-1 construct contains one copy of a 2.5-kb aggrecan gene fragment on which the AgE sequence is present from positions ϩ219 to ϩ247 containing two E-box sequences (CATCTG and CAGGTG), whereas the mAgCAT-1 construct contains one copy of a 2.5-kb aggrecan gene fragment in which the AgE sequence from positions ϩ219 to ϩ247 containing two E-box sequences (CATCTG and CAGGTG; mAgE sequence) has been replaced with substitution mutations (CATCTG to AAAAAA and CAGGTG to TTTTTT). B, ROS17/2.8 cells were cotransfected with 1 g of reporter plasmid, mAgCAT-1 (lanes 1-4) or AgCAT-1 (lanes 5-8) , and 1 g of scleraxis (Scx) expression vector ( lanes 3, 4, 7, 8, 11 , and 12) or 1 g of Bluescript SK ϩ (lanes 1, 2, 5, 6, 9, and 10). The cells were also transfected with pSV2CAT as a positive control (lanes 9 -12) . The transfected cells were cultured in F-12 medium supplemented with 5% FBS for 24 h. CAT activity was determined as described under "Materials and Methods." is the suppression of the osteoblast phenotype, i.e. suppression of type I collagen and alkaline phosphatase mRNA expression (Fig. 1) . Osteocalcin mRNA expression was suppressed in one scleraxis-overexpressing clone, but was not affected in the other (data not shown). Osteopontin expression is enhanced strongly by scleraxis in ROS17/2.8 cells. It is, however, known that osteopontin is expressed in both cartilage and bone (8) . Positive and negative functions are known in myogenic differentiation factors such as MyoD and myogenin (1) (2) (3) in the case of muscle differentiation. In this case, MyoD enhances musclespecific gene expression and at the same time suppresses nonmuscle phenotype expression. Similar to these observations, scleraxis could have a dual function; one is to enhance expression of chondrogenic phenotypes and the other is to suppress that of nonchondrogenic (in our case, osteoblastic) phenotypes.
Basic helix-loop-helix-type transcription factors are known to bind to cis-regulatory elements in the promoter regions of target genes, and scleraxis/E12 heterodimers have been reported to bind to the E-box sequence (CANNTG), with a preference for the middle two nucleotides as TG or CA. The AgE region in the first exon of the aggrecan gene contains two E-boxes gapped by three nucleotides at positions ϩ226 and ϩ240. The middle two nucleotides in these E-boxes are TC and GG. This difference could be related to our observation that the AgE sequence binds in vitro translated scleraxis in the absence of E protein. Alternatively, the presence of two E-boxes in tandem could also facilitate scleraxis binding without E protein. It is noteworthy that the previously reported E-box sequence (ScxE) that requires heterodimers of scleraxis and E protein for binding (12) is not from skeletal tissue-specific genes. This E-box sequence was actually derived from the promoter in a muscle-specific gene (muscle creatinine kinase). Cserjesi et al. (12) did not know any scleraxis target genes at that time; they screened only E-boxes that were known at that time. Since the aggrecan gene is the first gene to be identified as a scleraxis target, our AgE sequence is the first authentic E-box for scleraxis binding. These features could be the possible reason for the scleraxis binding to AgE without E protein.
In summary, we found that scleraxis overexpression enhanced aggrecan gene expression in osteoblastic ROS17/2.8 cells while it modulated osteoblastic phenotype expression. These features support the hypothesis that scleraxis is one of the key regulatory transcription factors in the modulation of chondrogenic and/or osteogenic differentiation.
